Antiangiogenic therapy

targeting vascular endothelial growth factor and its receptors.

Anita Tandle, Steven K. Libutti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Angiogenesis is an important natural process occurring in the body, both in health and in infirmity, that is controlled by angiogenesis-stimulating growth factors and angiogenesis inhibitors. Uncontrolled angiogenesis in a tumor can result in both tumor growth and metastasis. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are major players in many human malignancies and contribute directly to disease outcome. There is compelling evidence indicating that the beneficial effects of VEGF and VEGFR can be targeted as antiangiogenic therapy. Many of the agents have shown promising results in cell culture preclinical and animal models. Some of these agents have been tested in clinical trials as well. This review discusses the clinical significance of VEGF/VEGFR in human cancer, summarizes the more recent progress in the field, and further emphasizes the current development of agents that block VEGFR/VEGFR as angiogenesis inhibitors and the therapeutic significance of these agents in clinical trials.

Original languageEnglish (US)
Pages (from-to)41-48
Number of pages8
JournalClinical advances in hematology & oncology : H&O
Volume1
Issue number1
StatePublished - Jan 2003
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor
Angiogenesis Inhibitors
Therapeutics
Neoplasms
Clinical Trials
Growth Inhibitors
Vascular Endothelial Growth Factor A
Intercellular Signaling Peptides and Proteins
Animal Models
Cell Culture Techniques
Neoplasm Metastasis
Health
Growth

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Antiangiogenic therapy : targeting vascular endothelial growth factor and its receptors. / Tandle, Anita; Libutti, Steven K.

In: Clinical advances in hematology & oncology : H&O, Vol. 1, No. 1, 01.2003, p. 41-48.

Research output: Contribution to journalArticle

@article{1a9e99e38b254a6aa2057df15c1f5027,
title = "Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.",
abstract = "Angiogenesis is an important natural process occurring in the body, both in health and in infirmity, that is controlled by angiogenesis-stimulating growth factors and angiogenesis inhibitors. Uncontrolled angiogenesis in a tumor can result in both tumor growth and metastasis. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are major players in many human malignancies and contribute directly to disease outcome. There is compelling evidence indicating that the beneficial effects of VEGF and VEGFR can be targeted as antiangiogenic therapy. Many of the agents have shown promising results in cell culture preclinical and animal models. Some of these agents have been tested in clinical trials as well. This review discusses the clinical significance of VEGF/VEGFR in human cancer, summarizes the more recent progress in the field, and further emphasizes the current development of agents that block VEGFR/VEGFR as angiogenesis inhibitors and the therapeutic significance of these agents in clinical trials.",
author = "Anita Tandle and Libutti, {Steven K.}",
year = "2003",
month = "1",
language = "English (US)",
volume = "1",
pages = "41--48",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "1",

}

TY - JOUR

T1 - Antiangiogenic therapy

T2 - targeting vascular endothelial growth factor and its receptors.

AU - Tandle, Anita

AU - Libutti, Steven K.

PY - 2003/1

Y1 - 2003/1

N2 - Angiogenesis is an important natural process occurring in the body, both in health and in infirmity, that is controlled by angiogenesis-stimulating growth factors and angiogenesis inhibitors. Uncontrolled angiogenesis in a tumor can result in both tumor growth and metastasis. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are major players in many human malignancies and contribute directly to disease outcome. There is compelling evidence indicating that the beneficial effects of VEGF and VEGFR can be targeted as antiangiogenic therapy. Many of the agents have shown promising results in cell culture preclinical and animal models. Some of these agents have been tested in clinical trials as well. This review discusses the clinical significance of VEGF/VEGFR in human cancer, summarizes the more recent progress in the field, and further emphasizes the current development of agents that block VEGFR/VEGFR as angiogenesis inhibitors and the therapeutic significance of these agents in clinical trials.

AB - Angiogenesis is an important natural process occurring in the body, both in health and in infirmity, that is controlled by angiogenesis-stimulating growth factors and angiogenesis inhibitors. Uncontrolled angiogenesis in a tumor can result in both tumor growth and metastasis. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are major players in many human malignancies and contribute directly to disease outcome. There is compelling evidence indicating that the beneficial effects of VEGF and VEGFR can be targeted as antiangiogenic therapy. Many of the agents have shown promising results in cell culture preclinical and animal models. Some of these agents have been tested in clinical trials as well. This review discusses the clinical significance of VEGF/VEGFR in human cancer, summarizes the more recent progress in the field, and further emphasizes the current development of agents that block VEGFR/VEGFR as angiogenesis inhibitors and the therapeutic significance of these agents in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=1142305730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1142305730&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 41

EP - 48

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 1

ER -